Organogenesis Holdings Inc (NASDAQ:ORGO) traded with an addition of $0.61 to $3.26 on Thursday, an upside of 23.02 percent. An average of 736,207 shares of common stock have been traded in the last five days. There was a gain of $0.80 in the past week, and it reached a new high 11 times over the past 12 months. The last 20 days have seen an average of 671,477 shares traded, while the 50-day average volume stands at 862,343.
ORGO stock has increased by 16.43% in the last month. The company shares reached their 1-month lowest point of $2.29 on 09/19/23. With the stock rallying to its 52-week high on 07/19/23, shares of the company touched a low of $1.79 and a high of $4.50 in 52 weeks. It has reached a new high 18 times so far this year and achieved 21.19% or $0.53 in price. In spite of this, the price is down -27.56% from the 52-week high.
Insider Transactions
ORGO stock investors should be aware that Organogenesis Holdings Inc (ORGO) stock had its last reported insider trading activity 169 days ago on Apr 12. In this transaction, the insider spent $51,772. 10% Owner, ERANI ALBERT, disposed of 25,000 shares at a price of $2.07 on Apr 12. The insider now owns more than $51,772 worth of shares.
Valuation Metrics
Organogenesis Holdings Inc (ORGO) has a trailing price-to-earnings (P/E) ratio of 43.06, which compares with the N/A for the broader industry. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.94, the price-to-book (PB) ratio at 1.58.
Financial Health
The quick ratio of Organogenesis Holdings Inc for the three months ended June 29 was 2.60, and the current ratio was 2.95, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.38 and a total debt to equity ratio of 0.45 for the quarter ending June 29. Organogenesis Holdings Inc’s EBITDA margin for the year ending June 29 is 10.38%, while its operating margin for the same period stands at 5.16%. Its gross profit as reported stood at $345.87 million compared to revenue of $450.89 million.
Earnings Surprise
For the three-month period that ended June 29, Organogenesis Holdings Inc had $63.49 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $5.32 million in the quarter, while revenues of -$2.97 million were shrunk -64.29%. The analyst consensus anticipated Organogenesis Holdings Inc’s latest quarter earnings to come in at $0.02 per share, but it turned out to be $0.04, a 100.00% surprise. For the quarter, EBITDA amounted to $15.16 million. Shareholders own equity worth $131.31 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Organogenesis Holdings Inc (ORGO) price momentum. RSI 9-day as of the close on 27 September was 80.16%, suggesting the stock is Overbought, with historical volatility in this time frame at 97.13%.
As of today, ORGO’s price is $2.67 +33.05% or $0.80 from its 5-day moving average. ORGO is currently trading +12.58% higher than its 20-day SMA and +51.87% higher than its 100-day SMA. However, the stock’s current price level is -27.32% below the SMA50 and +21.50% above the SMA200.
The stochastic %K and %D were 85.99% and 66.57%, respectively, and the average true range (ATR) was 0.20. With the 14-day stochastic at 92.97% and the average true range at 0.19, the RSI (14) stands at 68.38%. The stock has reached 0.28 on the 9-day MACD Oscillator while the 14-day reading was at 0.26.
Analyst Ratings
Morgan Stanley launched coverage on Organogenesis Holdings Inc (NASDAQ: ORGO) in its analyst report released on June 15, 2023. The firm assigned the stock an Equal-weight rating. The consensus rating for Organogenesis Holdings Inc (ORGO) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ORGO, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is ORGO’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $4.00, with a median target of $3.50. Taking a look at these predictions, the average price target given by analysts for Organogenesis Holdings Inc (ORGO) stock is $3.50.
